123 related articles for article (PubMed ID: 35680546)
21. Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta-analysis.
Zhong J; Su Z; Zhang Y; Zhang H; Lin P; Tang X; Zheng R
J Ultrasound Med; 2018 Aug; 37(8):1881-1890. PubMed ID: 29380404
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of chondroitin sulphate proteoglycans in rat hepatocellular carcinoma tissues.
Jia XL; Li SY; Dang SS; Cheng YA; Zhang X; Wang WJ; Hughes CE; Caterson B
World J Gastroenterol; 2012 Aug; 18(30):3962-76. PubMed ID: 22912547
[TBL] [Abstract][Full Text] [Related]
23. A CT technique to evaluate the development of carcinogen-induced neoplasia in the rat liver.
Silverman PM; Popp JA; Swenberg JA; Putman CE
Invest Radiol; 1985; 20(3):267-71. PubMed ID: 4030264
[TBL] [Abstract][Full Text] [Related]
24. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST.
Liu M; Lin MX; Lu MD; Xu ZF; Zheng KG; Wang W; Kuang M; Zhuang WQ; Xie XY
Eur Radiol; 2015 Aug; 25(8):2502-11. PubMed ID: 25702094
[TBL] [Abstract][Full Text] [Related]
25. Piperlongumine inhibits diethylnitrosamine induced hepatocellular carcinoma in rats.
Kumar A; Naithani M; Kumar N; Singh N; Agrawal S; Sharma A; Thapliyal S; Singh J; Handu S
Hum Exp Toxicol; 2022; 41():9603271211073593. PubMed ID: 35113675
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation.
Kisaka Y; Hirooka M; Kumagi T; Uehara T; Hiasa Y; Kumano S; Tanaka H; Michitaka K; Horiike N; Mochizuki T; Onji M
Liver Int; 2006 Dec; 26(10):1241-7. PubMed ID: 17105590
[TBL] [Abstract][Full Text] [Related]
27. Involvement of NF-κB/PI3K/AKT signaling pathway in the protective effect of prunetin against a diethylnitrosamine induced hepatocellular carcinogenesis in rats.
Li G; Qi L; Chen H; Tian G
J Biochem Mol Toxicol; 2022 May; 36(5):e23016. PubMed ID: 35239232
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor effects of cimetidine on hepatocellular carcinomas in diethylnitrosamine-treated rats.
Furuta K; Sato S; Miyake T; Okamoto E; Ishine J; Ishihara S; Amano Y; Adachi K; Kinoshita Y
Oncol Rep; 2008 Feb; 19(2):361-8. PubMed ID: 18202782
[TBL] [Abstract][Full Text] [Related]
29. Identification of the Potential Metabolic Pathways Involved in the Hepatic Tumorigenesis of Rat Diethylnitrosamine-Induced Hepatocellular Carcinoma via
Chen M; Lu S; Zheng H; Xu M; Song J; Yang W; Weng Q; Zheng L; Fan X; Cheng X; Gao H; Ji J
Biomed Res Int; 2019; 2019():9367082. PubMed ID: 30719453
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.
Alaboudy A; Inoue T; Hatanaka K; Chung H; Hyodo T; Kumano S; Murakami T; Moustafa EF; Kudo M
Oncology; 2011; 81 Suppl 1():66-72. PubMed ID: 22212939
[TBL] [Abstract][Full Text] [Related]
31. Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma.
D'Souza JC; Sultan LR; Hunt SJ; Gade TP; Karmacharya MB; Schultz SM; Brice AK; Wood AKW; Sehgal CM
Nanotheranostics; 2019; 3(4):331-341. PubMed ID: 31687321
[No Abstract] [Full Text] [Related]
32. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
33. Assessment of angiogenesis of hepatocellular carcinoma using dynamic contrast enhanced MR and histopathologic correlation in an experimental rat model.
Lee JH; Park MJ; Kim JK; Kim YC; Kim TH; Park MS; Yu JS; Kim KW; Kim YB; Kim SH; Shim W; Kim D; Yun CO; Ahn SH
Hepatogastroenterology; 2014; 61(130):447-52. PubMed ID: 24901159
[TBL] [Abstract][Full Text] [Related]
34. Suppression of beta-catenin mutation by dietary exposure of auraptene, a citrus antioxidant, in N,N-diethylnitrosamine-induced hepatocellular carcinomas in rats.
Hara A; Sakata K; Yamada Y; Kuno T; Kitaori N; Oyama T; Hirose Y; Murakami A; Tanaka T; Mori H
Oncol Rep; 2005 Aug; 14(2):345-51. PubMed ID: 16012713
[TBL] [Abstract][Full Text] [Related]
35. Sequential analysis and staging of a diethylnitrosamine-induced hepatocellular carcinoma in male Wistar albino rat model.
Fathy AH; Bashandy MA; Bashandy SAE; Mansour AM; Elsadek B
Can J Physiol Pharmacol; 2017 Dec; 95(12):1462-1472. PubMed ID: 28854340
[TBL] [Abstract][Full Text] [Related]
36. Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.
Zhang W; Chen HJ; Wang ZJ; Huang W; Zhang LJ
Eur Radiol; 2017 May; 27(5):2086-2094. PubMed ID: 27488851
[TBL] [Abstract][Full Text] [Related]
37. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI?
Tan Z; Teoh WC; Wong KM; Wansaicheong GK; Sandrasegaran K
Clin Imaging; 2020 Jun; 62():63-68. PubMed ID: 32070868
[TBL] [Abstract][Full Text] [Related]
38. Image fusion of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) using volume navigation for detection, characterization and planning of therapeutic interventions of liver tumors.
Rennert J; Georgieva M; Schreyer AG; Jung W; Ross C; Stroszczynski C; Jung EM
Clin Hemorheol Microcirc; 2011; 49(1-4):67-81. PubMed ID: 22214679
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and application of strawberry-like Fe3O4-Au nanoparticles as CT-MR dual-modality contrast agents in accurate detection of the progressive liver disease.
Zhao HY; Liu S; He J; Pan CC; Li H; Zhou ZY; Ding Y; Huo D; Hu Y
Biomaterials; 2015 May; 51():194-207. PubMed ID: 25771010
[TBL] [Abstract][Full Text] [Related]
40. Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging?
Park SH; Kim B; Kim SY; Choi SJ; Huh J; Kim HJ; Kim KW; Lee SS
Korean J Radiol; 2020 Mar; 21(3):280-289. PubMed ID: 32090520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
